Abstract
Recent progress in the understanding of seven-transmembrane receptor (7TMR) signalling has promoted the development of a new generation of pathway selective ligands. The angiotensin II type I receptor (AT1aR) is one of the most studied 7TMRs with respect to selective activation of the β-arrestin dependent signalling. Two complimentary global phosphoproteomics studies have analyzed the complex signalling induced by the AT1aR. Here we integrate the data sets from these studies and perform a joint analysis using a novel method for prediction of differential kinase activity from phosphoproteomics data. The method builds upon NetworKIN, which applies sophisticated linear motif analysis in combination with contextual network modelling to predict kinase-substrate associations with high accuracy and sensitivity. These predictions form the basis for subsequently nonparametric statistical analysis to identify likely activated kinases. This suggested that AT1aR-dependent signalling activates 48 of the 285 kinases detected in HEK293 cells. Of these, Aurora B, CLK3 and PKG1 have not previously been described in the pathway whereas others, such as PKA, PKB and PKC, are well known. In summary, we have developed a new method for kinase-centric analysis of phosphoproteomes to pinpoint differential kinase activity in large-scale data sets.
Introduction
Getting an overview of the complex propagation of cellular signal transduction is important to understand the process from receptor activation to phenotypic outcomes. Protein phosphorylation is central to cellular signalling and can be systematically investigated using quantitative mass spectrometry (MS) [1], [2]. Global analysis of ligand induced changes in phosphorylation can be achieved using stable isotopic labelling of amino acids in cell culture (SILAC)[2]. In a typical SILAC setup, two or three cell cultures are grown in parallel, one on a medium with regular amino acids and one or two on a medium with isotopically labelled amino acids. Once the cell cultures have almost fully incorporated the isotopic labelled amino into their proteomes, they can be differentially stimulated, lysed, mixed and jointly analysed in the mass spectrometer to minimize unwanted biases. Peptides from the two experimental conditions can be differentiated from the known molecular weight difference arising from the labelled amino acids [3]. In this study, we present a joint analysis of two complimentary SILAC-based phosphoproteomics studies that have portrayed the complex signalling induced by the angiotensin II type 1 receptor (AT1aR) [4], [5].
AT1aR (Figure 1) is an important cardiovascular seven transmembrane receptor (7TMR). It has been one of the first and most important receptors for defining the concept of functional selectivity, i.e. that selective ligands can have agonistic effects on one signalling pathway while antagonizing another [7]. Traditionally, drugs that target 7TMRs have been described as either agonists or antagonists, based on their ability to induce or inhibit G-protein dependent signalling. The discovery that one ligand can differentially affect multiple signalling pathways represents an enormous potential for the development of drugs which might have less side effects or be more efficacious. Biased agonists inhibiting the AT1aR G-protein dependent signalling while preserving β-arrestin signalling have a promising profile for treatment of cardiac diseases as they largely separate the G-protein initiated hypertensive and hypertrophic effects from the β-arrestin-mediated cardioprotective and regenerative mechanisms [8]–[10]. Although much is known about the molecular mechanisms leading to functional ligand selectivity and the first steps in the separation of the major signalling pathways, it remains challenging to get an overview of the complex signalling induced by the AT1aR. Christensen and co-workers compared the effect of the natural agonist Ang II and the β-arrestin selective agonist SII Ang II [4], whereas Xiao and co-workers focused on the signalling initiated by SII Ang II [5]. The two studies were designed similar and are thus comparable. Due to the partly stochastic nature of mass spectrometry [6] and minor differences in peptide isolation methods used in the studies, combining the two studies can provide a more comprehensive description of the AT1aR signalling than any of the studies alone.
To gain further insight into the function of the modifications identified in phosphoproteomics studies, multiple approaches can be used to predict the activity of kinases based on the regulated phosphopeptides. The activities of many kinases are themselves regulated through phosphorylation, and Xiao and co-workers supplemented their mass spectrometry data with an antibody array against known regulatory phosphorylation sites on a panel of kinases; however, both datasets contain many phosphorylation sites on kinases, for which the effect on kinase activity remains to be elucidated. Algorithms like the kinase enrichment analysis compare the regulated proteins to a background database of known interactions [11]. As this approach relies solely on protein interaction and not specific phosphosites, it disregards the fact that the majority of substrates can have several phosphosites and that these sites are not necessarily targeted by the same kinase. Conversely, tools like Motif-X [12], which identify over-represented sequence motifs, are able to differentiate between multiple modification sites but ignore the cellular context [13]–[15]. However, it is difficult to pinpoint the specific kinases, as many of them recognise substrates with similar or identical sequence motifs [16].
To address these issues, the NetworKIN algorithm combines sequence motifs with data on cellular context in the form of protein interactions to reliably assign kinases to their corresponding modification sites [17]. Here, we present an approach that compares the NetworKIN score distributions for each kinase under two conditions to identify kinases with differential activity. We illustrate the power of this approach by applying it to the combined phosphoproteomics data set on AT1aR -mediated signalling.
Results and Discussion
Combining the two AT1aR phosphoproteomes
The phosphoproteomics study of AT1aR signalling by Christensen and co-workers reported 1182 individual phosphosites on 530 proteins to be up-regulated by Ang II or SII Ang II [4]. Hereof, the SII Ang II dependent subset; induced by the β-arrestin biased agonist SII Ang II is 36% or 424 phosphosites on 204 proteins. The study by Xiao and co-workers, which focused on β-arrestin dependent signalling induced by SII Ang II stimulation, revealed 207 up-regulated phosphosites on 146 unique proteins[5]. The two studies use different methods to enrich for phosphopeptides, namely immobilized metal affinity chromatography (IMAC) and titanium dioxide (TiO2). Although both methods generate reproducible results, the concentrations used vary slightly as do the stimulation time. In addition, they have different preferences for phosphopeptides, and are thus complementary to each other [18].
We combined both studies to obtain a total of 1339 up-regulated phosphosites on 605 proteins. The SII Ang II dependent signalling subset comprised of 600 SII Ang II up-regulated phosphosites on 299 proteins (Table S1). As expected given the biological and experimental differences between the two studies, the overlap in SII Ang II dependent signalling is small: only 31 of the 600 phosphosites (5%) were found in both studies. However, the overlap is considerably higher at the level of proteins, with 51 of the 299 phosphorylated proteins (17%) being identified in both studies (Figure 2A). This shows that many proteins involved in β-arrestin dependent AT1aR signalling are phosphorylated on several residues, with the two studies identifying different sites in the same proteins. On average two phosphosites were identified per protein; the distribution of the number of phosphosites per protein is shown in Figure 3.
Prediction of differences in kinase activity profiles
To predict the differential activity of kinases, we run the NetworKIN algorithm on all 1339 up-regulated sites identified in the studies (Table S2). NetworKIN covers a list of 207 protein kinases, however not all may be present in HEK293 cells. In a separate experiment we examined the expression of kinases in AT1aR HEK293 cells (Table S3). By combining this experiment and the two proteomes provided by Xiao and Christensen, we found a total of 285 protein kinases to be expressed in AT1aR HEK293 cells. Comparing the list of the detected protein kinases to the kinases included in NetworKIN (Table S3) showed that 121 of the 285 detected protein kinases are included in NetworKIN. To account for this, we filtered the prediction results to include only protein kinases known to be expressed in the HEK293 cells in the analysis. Figure 4 illustrates the overlap of the kinases found in the studies with the kinases supported by the NetworKIN algorithm.
NetworKIN scores represent how likely a site is to be modified by a specific kinase. By comparing the NetworKIN score distributions for the same kinase under two different conditions, we can identify statistically significant differences and thereby predict changes in kinase activity between the conditions (Figure S1). The scores in NetworKIN are relative scores, normalized for the proteome-wide score distribution for each kinase specific predictor. Scores are furthermore log-transformed to increase the resolution in the high scoring range: a score of 2 or 3 corresponds to a prediction better than 99.9% or 99.99%, respectively, of all scores in the proteome for the specific kinase. The plot for PKCδ (Figure 5a) exemplifies a kinase predicted to be active, which is reflected in a significant shift towards higher scores for the up-regulated sites. By contrast, the score distributions for CK1γ3 (Figure 5b) illustrate a non-regulated kinase, with a non significant difference between the regulated and non-regulated sites. The analysis also allows for detection of down-regulated kinases like CLK1 (Figure 5c), which shows a shift towards lower scores for the regulated sites.
The statistical analysis of up-regulated versus non-regulated phosphosites suggested increased activity for 48 and decreased activity for 10 of the 121 kinases (Table 1, Figure 6). The vast majority (89%) of the 48 activated kinases are known to be involved in angiotensin II signalling, validating the approach, and 26 of them harbour regulated phosphosites reported in the two studies (P<0.0001; Fishers exact test). Among these we found ERK1/2, RSK2 and p70S6, for which the phosphosites have been linked to kinase activity. Furthermore, the method suggested increased activity of well-known Ang II regulated kinases, e.g. GRK5/6 and PKC, which were not found to be phosphorylated themselves.
Table 1. NetworKIN predicted active kinases.
Name | Phosphosites | Ref |
AKT1 | Ser129, Thr308* | 5 |
AKT2 | ||
AKT3 | ||
AMPKa1 | Ser497;Thr183* | 4; 5 |
AMPKa2 | Thr172* | 5 |
ARAF | Thr181, Ser186 | 4 |
AuroraB | ||
BRAF | Ser151 | 4 |
CaMKIIβ | ||
CaMKIIδ | Ser330, Ser333, Ser334, Ser337 | 4 |
CaMKIIγ | ||
CLK3 | ||
DMPK2 | ||
MRCKa | Ser1673, Ser1676 | 4 |
MRCKb | ||
GRK2 | Ser685 | 4 |
GRK3 | ||
GRK5 | ||
GRK6 | ||
JNK1 | Thr183*,Tyr185* | 5 |
JNK2 | Thr183*,Tyr185* | 5 |
MAP2K1 | Ser218*,Ser222* | 5 |
MAP2K2 | Thr394, Thr396 Ser222*,Ser226* | 4;5 |
ERK1 | Thr198, Thr202*, Tyr204* | 4 |
ERK2 | Thr185*, Tyr187* | 4 |
p38α | Thr180*, Tyr182* | 5 |
p38β | ||
p70S6K | Ser441, Thr444, Ser205; Thr252*, Ser394*, Thr412* | 4 |
p70S6Kb | Ser416, Ser417, Ser423; Thr228*, Ser370*, Thr388* | 4 |
PAK1 | ||
PAK2 | Thr169 | 5 |
PAK4 | Ser291 | 5 |
PKCα | ||
PKCδ | ||
PKCι | ||
PKCθ | ||
PKD1 | Ser205, Ser208, Ser210, Ser237, Thr395, Ser397, Ser401; S742* | 4; 5 |
PKD2 | Ser197, Ser198, Thr199, Ser203, Ser396 | 4 |
PKD3 | Ser41, Ser44 | 4 |
PKG1 | ||
PKAα | ||
PKAβ | ||
ROCK1 | ||
ROCK2 | Ser1137 | 4 |
RSK1 | Thr359, Ser363, Ser369, Ser372, Ser733; Ser221*, Ser380* | 4; 5 |
RSK2 | Thr365, Ser369, Ser375; S227*, S386* | 4; 5 |
RSK3 | Ser377* | 5 |
RSK4 |
Phosphorylation sites from the two proteomic studies were analysed using the NetworKIN algorithm and the predictions were filtered based on kinases detected in the AT1aR-HEK kinome. NetworKIN verified the activity of many of the kinases found by phospho-antibody array by Xiao et al., 2010 and predicted activity for several other kinases, of which around half have been described in the literature of angiotensin II signalling. Numbering of amino acids is according to SwissProt. Amino acids marked * are involved in the regulation of the kinase (SwissProt). Kinases that have not previously been described to be regulated in the angiotensin II signaling pathway are depicted in bold. Phosphorylation sites detected in either of the two proteomic studies Christensen et al., 2010 and Xiao et al., 2010 are denoted Ref. 4 and 5, respectively.
Three of the kinases we predict to be activated had not previously been described as regulated by Ang II or as involved in cardiac pathology when the analysis was performed. These are Aurora kinase B (Aurora B), Dual specificity protein kinase CLK3 and cGMP-dependent protein kinase 1 (PKG1). Recently, Aurora B was shown to phosphorylate certain histone deacetylases (HDACs) with critical roles in cardiac disease and thereby likely regulate their localization [19]. PKG1 is involved in vascular smooth muscle relaxation, where it influences actin binding by the phosphorylation of proteins important for cytoskeletal reorganisation [20] which fits well with regulation by Ang II. In addition to predicting active kinases, the statistical analysis of the NetworKIN predictions revealed that the p-value for some kinases were non-significant, indicating that their activity were neither up- nor down-regulated despite Ang II induced phosphorylation of the kinase (e.g. GSK3α, GSK3β, and CDK1).
Despite the lack of up-regulated phosphosites on the constitutively active kinase CK2 our statistical analysis suggests that CK2a and CK2a2 are both inactivated (Figure S1 and Table S4). The statistical analysis furthermore predicts reduced activity of the kinases ATM, ATR, CDK2, CDK3, CK2, CLK1, CLK4 and TLK1.
Tyrosine phosphorylation in the AT1aR signalosome
Several earlier studies on AT1aR signalling have described angiotensin II mediated tyrosine phosphorylation [21]–[25]. Proteins harbouring these are often low abundant [2] and in addition current enrichment methods favour peptides phosphorylated on serines or threonines [18]. This leads to tyrosine phosphorylation being significantly underreported; in the two studies the fraction of tyrosine sites was 0.7% and 3.3% for the studies by Christensen and co-workers and Xiao and co-workers respectively (Figure 2B). However, by analysing a human phosphorylation-antibody array, Xiao and co-workers showed the activation of several tyrosine kinases in response to SII Ang II stimulation (SRC, FAK, HCK, FGR, LYN, LCK, and YES1), indicating that the bias against tyrosine sites indeed arises from experimental limitations.
Analysis of the phosphoproteome reveals multiple regulated parallel pathways
To generate an overview of the AT1aR signalling in the form of pathway maps, we performed enrichment analysis of all 605 proteins. The enrichment analysis searches for a larger-than-expected overlap between the input list of proteins and e.g. the members of a known pathway. If a statistically significant number of proteins from the query list are members of the pathway, it may indicate that this pathway plays a role in the studied condition. We analysed the combined data set using the MetaCore algorithm (http://www.genego.com/metacore.php). However, the algorithm was only able to map 265 of the 605 proteins, indicating that several proteins remain to be assigned a function in a signalling context in the MetaCore algorithm.
The analysis revealed that a number of signalling pathways are regulated by angiotensin II. Among these were pathways previously implicated in cross-talk with angiotensin II signalling, namely insulin [26] and EGFR [27], [28] signalling. The data also points to angiotensin II mediated regulation of the WNT pathway [29] (AKT, APC, GSK3β, β-catenin, TCF7L2 and Bcl-9-2). The 10 highest-ranking pathways are shown in Table 2. The most significant enriched pathway was the G-protein coupled receptor Gastrin. AT1aR and the Gastrin receptor both signal through the same G-proteins (Gαq/11) and share many proteins in their downstream signalling cascades. This explains the presence of many additional GPCR signalling pathways in the list of the significantly enriched pathways. However, angiotensin II signalling was not among the list of these, suggesting that according to MetaCore, a minority of the phosphorylated proteins are described in the pathway. In MetaCore the angiotensin II pathway have been divided into 2 maps, the “Angiotensin signalling via β-arrestin” and “Angiotensin via PYK” (the 2 maps are available at http://pathwaymaps.com/maps/, however not all maps in the MetaCore algorithm are freely available). We merged the two maps, thereby creating one map for the angiotensin II pathway, thus illustrating how many of the involved proteins were regulated. Reanalysis of the enrichment analysis including the merged angiotensin II pathway map, placed the angiotensin II pathway map as the top-scoring map.
Table 2. The AT1aR regulated pathway maps.
Group | Name of the map | pValue | ratio |
Development | Gastrin in cell growth and proliferation | 5,09E-18 | 22/62 |
Cytoskeleton remodeling | Cytoskeleton remodeling | 5,91E-15 | 24/102 |
Development | FGFR signaling pathway | 1,46E-14 | 18/53 |
Cytoskeleton remodeling | TGF, WNT and cytoskeletal remodeling | 4,51E-14 | 24/111 |
Development | Flt3 signaling | 1,29E-13 | 16/44 |
Development | Thrombopoietin-regulated cell processes | 1,94E-13 | 16/45 |
Regulation of lipid metabolism | Insulin signaling:generic cascades | 4,26E-13 | 16/47 |
Chemotaxis | CXCR4 signaling pathway | 5,98E-13 | 14/34 |
Development | A2B receptor: action via Gprotein alpha s | 1,28E-12 | 16/50 |
Immune response | IL15 signaling | 7,41E-12 | 17/64 |
The phosphopeptides regulated by Ang II or/and SII Ang II was used for enrichment analysis in MetaCore (GeneGo). The enrichment analysis retrieved a list of pathways from the database. The 10 most significant pathways are shown. The majority of the pathways are in good agreement with the current knowledge of angiotensin II signalling.
To illustrate the interconnection and the broad overlap between the top-5 scoring pathways and the merged angiotensin II pathway map, we combined the maps in MetaCore. In order to aid the clarity of the combined map, unregulated parts of top-5 scoring pathways were removed. This illustrates an overview of the regulated proteins and their interconnections (Figure S2).The integrated map shows, that 19 of the 43 proteins on the angiotensin II pathway map are regulated by both G-protein dependent and independent signalling (Figure S2). This is in agreement with previous studies, which have shown that both signalling mechanisms activate the MAP kinases ERK1/2 [30]. Despite what we know of separate G-protein and β-arrestin dependent pathways initiated by AT1aR [30]-, the map does not contain sub clusters of proteins solely regulated by the G-protein dependent Ang II pathway.
Previous studies have shown that the MAP kinases ERK1/2 are activated by both G-protein dependent and independent signalling mechanisms [30]. G-protein dependent Ang II signalling leads to nuclear localisation of ERK1/2, whereas ERK1/2 activated by G-protein independent SII Ang II stimulus is restricted to the cytoplasm, an example of two parallel pathways affecting the same signalling proteins. G-protein independent signal transduction has been linked to cell survival and renewal [33], [34], but do surprisingly not regulate significant gene expression [35], [36]. The exact signalling pathway giving rise to G-protein independent nuclear effects mediating proliferative effects remain to be elucidated. In summary, we present a novel workflow for the prediction of differential active kinases by statistically comparing the NetworKIN scores in the non-stimulated and stimulated conditions. The NetworKIN usage of phosphosites as “fingerprints” for activity of kinases in combination with knowledge on protein-protein interaction provides additional valuable information about the signalling backbone in the original phosphoproteomics analysis. The confidence in our results is strengthened by the fact, that we predict kinases well known to be regulated by angiotensin II. Overall, this study provides a global unbiased overview of the AT1aR signaling, hereunder the G-protein dependent and – independent components, and predicts a new set of kinases and other target proteins to study in the coming years, which will be helpful in directing research to increase the knowledge of this important cardiovascular regulator.
Materials and Methods
Data description
We mapped the list of regulated phosphosites from Xiao and co-workers [5] to UniProt sequences and subsequently combined them with the results of Christensen and co-workers [4]. Xiao and co-workers [5] used the Ambiguity score algorithm for localization of phosphosites, while Christensen and colleagues [4] used the Mascot decoy score. Since the scope of this paper is not to evaluate these two algorithms, we have chosen to rely on the authors' confidence in the used algorithms and thus localization of the phosphosites.
In the case of contradictory results for the regulation of phosphorylation sites, e.g. sites reported as up-regulated in one and detected but not up-regulated in the other study, we curated the data. We defined these borderline significant sites as regulated, if the fold-change in the study reporting it as not up-regulated was higher than 1.4.
NetworKIN
The 1339 up-regulated phosphosites were analysed by NetworKIN v3 [17]. The NetworKIN algorithm predicts kinase-substrate interactions based on sequence motifs and cellular context. The NetworKIN results are relative scores, normalized for the proteome-wide score distribution for each kinase-specific predictor. Scores are furthermore log-transformed to increase the resolution in the high scoring range. A score of 2 or 3 corresponds to a prediction better than 99.9% or 99.99% respectively of all scores in the proteome for the specific kinase.
Statistics
As background data set we used the prediction of the 9500 non-regulated phosphosites published in [4]. The Kolmogorov-Smirnov test (KS test) was used to compare score distributions between the two sets. Kolmogorov-Smirnov is a nonparametric test for the equality of continuous one-dimensional probability distributions. The p-value indicates how alike the background distribution and the up-regulated score distribution for a given kinase is. A smaller p-value indicates a more significant difference in the distributions. With a p-value less than 0.05 we expect that in 5 of 100 instances we would wrongly claim two equal distributions to be different, thus wrongly claiming the kinase differential active. As distributions for 121 kinases were analysed, it is likely that by random chance we find kinases with significant difference in distributions. In order to reduce this we correct for multiple testing by correcting the p-values for false discovery rate correction (Benjamini-Hochberg method). A stringent p-value of 0.005 was applied. To discriminate between active and inactive kinases, we calculated p-values for the likelihood of the regulated phosphosites being shifted towards higher or lower scores compared to the non-regulated (one-sided KS test).
Kinases in AT1aR-HEK
NetworKIN supports predictions for 207 protein kinases. However, not all of the 207 kinases are expressed in AT1aR HEK293 cells used in the studies, while the algorithm does not support all expressed kinases. Therefore, we limited our analysis to the kinases in the overlap between the kinases supported by NetworKIN, the combined list of kinases found in the two experiments and an in-house AT1aR HEK293 proteome (Suppl. 2).
Pathway analysis
In order to determine which pathways were affected downstream of the AT1aR, we analysed the 605 proteins with up-regulated phosphosites in Metacore (http://www.genego.com/metacore.php). The program analysed the list of proteins for pathway enrichment, using the MetaCore database as background.
Supporting Information
Funding Statement
We thank the following for financial support: The Danish Heart Association, The Danish Council for Independent Research | Medical Sciences, the Danish National Research Foundation and The Købmand i Odense Johan og Hanne Weimann f. Seedorffs legat. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Kruger M, Kratchmarova I, Blagoev B, Tseng YH, Kahn CR, et al. (2008) Dissection of the insulin signaling pathway via quantitative phosphoproteomics. Proc Natl Acad Sci U S A 105: 2451–2456. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Olsen JV BB, Gnad F, Macek B, Kumar C, Mortensen P, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. cell 127: 13. [DOI] [PubMed] [Google Scholar]
- 3. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, et al. (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1: 376–386. [DOI] [PubMed] [Google Scholar]
- 4. Christensen GL KC, Lyngsø C, Sarwar U, Bøgebo R, Sheikh SP, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9: 13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Xiao K SJ, Kim J, Rajagopal S, Zhai B, Villén J, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107: 35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Mallick P, Schirle M, Chen SS, Flory MR, Lee H, et al. (2007) Computational prediction of proteotypic peptides for quantitative proteomics. Nat Biotechnol 25: 125–131. [DOI] [PubMed] [Google Scholar]
- 7. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320: 1–13. [DOI] [PubMed] [Google Scholar]
- 8. Aplin M, Christensen GL, Hansen JL (2008) Pharmacologic perspectives of functional selectivity by the angiotensin II type 1 receptor. Trends Cardiovasc Med 18: 305–312. [DOI] [PubMed] [Google Scholar]
- 9. Christensen GL, Aplin M, Hansen JL (2010) Therapeutic potential of functional selectivity in the treatment of heart failure. Trends Cardiovasc Med 20: 221–227. [DOI] [PubMed] [Google Scholar]
- 10. Sauliere A, Bellot M, Paris H, Denis C, Finana F, et al. (2012) Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat Chem Biol 8: 622–630. [DOI] [PubMed] [Google Scholar]
- 11. Lachmann A MaA (2009) KEA: kinase enrichment analysis. Bioinformatics 25: 3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Schwartz D GS (2005) An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets. Nat Biotechnol 23: 8. [DOI] [PubMed] [Google Scholar]
- 13. Rinschen MM, Yu MJ, Wang G, Boja ES, Hoffert JD, et al. (2010) Quantitative phosphoproteomic analysis reveals vasopressin V2-receptor-dependent signaling pathways in renal collecting duct cells. Proc Natl Acad Sci U S A 107: 3882–3887. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Reiland S, Messerli G, Baerenfaller K, Gerrits B, Endler A, et al. (2009) Large-scale Arabidopsis phosphoproteome profiling reveals novel chloroplast kinase substrates and phosphorylation networks. Plant Physiol 150: 889–903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Zhai B, Villen J, Beausoleil SA, Mintseris J, Gygi SP (2008) Phosphoproteome analysis of Drosophila melanogaster embryos. J Proteome Res 7: 1675–1682. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Linding R, Jensen LJ, Ostheimer GJ, van Vugt MA, Jorgensen C, et al. (2007) Systematic discovery of in vivo phosphorylation networks. cell 129: 1415–1426. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Linding R JL, Pasculescu A, Olhovsky M, Colwill K, Bork P, et al. (2008) NetworKIN: a resource for exploring cellular phosphorylation networks. Nucleic Acids Res 36: 4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Bodenmiller B, Mueller LN, Mueller M, Domon B, Aebersold R (2007) Reproducible isolation of distinct, overlapping segments of the phosphoproteome. Nat Methods 4: 231–237. [DOI] [PubMed] [Google Scholar]
- 19. Guise AJ, Greco TM, Zhang IY, Yu F, Cristea IM (2012) Aurora B-dependent regulation of class IIa histone deacetylases by mitotic nuclear localization signal phosphorylation. Mol Cell Proteomics 11: 1220–1229. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Butt E GS, Göttfert N, Galler A, Marcus K, Meyer HE (2003) Actin binding of human LIM and SH3 protein is regulated by cGMP- and cAMP-dependent protein kinase phosphorylation on serine 146. J Biol Chem 278: 6. [DOI] [PubMed] [Google Scholar]
- 21. Ali MS, Sayeski PP, Dirksen LB, Hayzer DJ, Marrero MB, et al. (1997) Dependence on the motif YIPP for the physical association of Jak2 kinase with the intracellular carboxyl tail of the angiotensin II AT1 receptor. J Biol Chem 272: 23382–23388. [DOI] [PubMed] [Google Scholar]
- 22. Ali MS (1997) Schieffer B, Delafontaine P, Bernstein KE, Ling BN, et al (1997) Angiotensin II stimulates tyrosine phosphorylation and activation of insulin receptor substrate 1 and protein-tyrosine phosphatase 1D in vascular smooth muscle cells. J Biol Chem 272: 12373–12379. [DOI] [PubMed] [Google Scholar]
- 23. Seta K, Sadoshima J (2003) Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin II-induced trans-activation of the epidermal growth factor receptor. J Biol Chem 278: 9019–9026. [DOI] [PubMed] [Google Scholar]
- 24. Seta K, Nanamori M, Modrall JG, Neubig RR, Sadoshima J (2002) AT1 receptor mutant lacking heterotrimeric G protein coupling activates the Src-Ras-ERK pathway without nuclear translocation of ERKs. J Biol Chem 277: 9268–9277. [DOI] [PubMed] [Google Scholar]
- 25. Ishida M, Marrero MB (1995) Schieffer B, Ishida T, Bernstein KE, et al (1995) Angiotensin II activates pp60c-src in vascular smooth muscle cells. Circ Res 77: 1053–1059. [DOI] [PubMed] [Google Scholar]
- 26. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, et al. (1996) Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci U S A 93: 12490–12495. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Thomas WG BY, Autelitano DJ, Pham T, Qian H, Hannan RD (2002) Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 90: 7. [DOI] [PubMed] [Google Scholar]
- 28. Shah BH CK (2003) A central role of EGF receptor transactivation in angiotensin II -induced cardiac hypertrophy. Trends Pharmacol Sci 24: 5. [DOI] [PubMed] [Google Scholar]
- 29. Clevers H NR (2012) Wnt/β-Catenin Signaling and Disease. Cell 149: 13. [DOI] [PubMed] [Google Scholar]
- 30. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ (2004) Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 279: 35518–35525. [DOI] [PubMed] [Google Scholar]
- 31. Aplin M, Christensen GL, Schneider M, Heydorn A, Gammeltoft S, et al. (2007) Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic Clin Pharmacol Toxicol 100: 296–301. [DOI] [PubMed] [Google Scholar]
- 32. Aplin M, Christensen GL, Schneider M, Heydorn A, Gammeltoft S, et al. (2007) The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. Basic Clin Pharmacol Toxicol 100: 289–295. [DOI] [PubMed] [Google Scholar]
- 33. Ahn S, Kim J, Hara MR, Ren XR, Lefkowitz RJ (2009) {beta}-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation. J Biol Chem 284: 8855–8865. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Hunton DL, Barnes WG, Kim J, Ren XR, Violin JD, et al. (2005) Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol Pharmacol 67: 1229–1236. [DOI] [PubMed] [Google Scholar]
- 35. Lee MH, El-Shewy HM, Luttrell DK, Luttrell LM (2008) Role of beta-arrestin-mediated desensitization and signaling in the control of angiotensin AT1a receptor-stimulated transcription. J Biol Chem 283: 2088–2097. [DOI] [PubMed] [Google Scholar]
- 36. Christensen GL, Knudsen S, Schneider M, Aplin M, Gammeltoft S, et al. (2011) AT(1) receptor Galphaq protein-independent signalling transcriptionally activates only a few genes directly, but robustly potentiates gene regulation from the beta2-adrenergic receptor. Mol Cell Endocrinol 331: 49–56. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.